Background Several studies have shown the effectiveness of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for type 2 diabetes, having a hypoglycemic effect being proven both when it is administered alone or in combination with additional oral antidiabetic agents. and body weight, were investigated retrospectively. Compliance with diet and exercise therapy at 48 weeks was checked by… Continue reading Background Several studies have shown the effectiveness of sitagliptin, a dipeptidyl